Completely reusable 3D cell culture microplate: December 2020 edition

Microbioz India, December , 2020 Issue


Cover Story : "Completely reusable 3D cell culture microplate: December 2020 edition"

Completely reusable 3D cell culture microplate: December 2020 edition

A microplate or microtiter plate (spelled Microtiter is a registered trade name in the United States), microwell plate, multiwell, is a flat plate with multiple "wells" used as small test tubes. The microplate has become a standard tool in analytical research and clinical diagnostic testing laboratories. eNUVIO announced the release of the first completely reusable 3D cell culture microplate on the market. Scientific research currently consumes high-volumes of single-use plastics - from serological pipettes and pipette tips to vials and culture microplates - these are just a few of the many plastic items thrown in the garbage in labs every day. eNUVIO’s completely reusable EB-Plate comes to the market at the right time as the demand for 3D cell culture microplates is high, conventional plastic plates are currently in short supply, and the zero waste movement is becoming increasingly popular in laboratories.  Read more   

INSIDE THIS ISSUE

The first completely reusable 3D cell culture microplate on the market

A microplate or microtiter plate (spelled Microtiter is a registered trade name in the United States), microwell plate, multiwell, is a flat plate with multiple “wells” used as small test tubes. The microplate has become a standard tool in analytical research Read more

Arctoris appoints three experienced industry executives as members of its Advisory Board

Arctoris Ltd, an Oxford-based research company operating a fully automated drug discovery platform, has appointed three distinguished experts Read more.

Cipla announces settlement of Revlimid® (Lenalidomide) capsules patent litigation

CIPLA EQ) (“Cipla”) today announced the settlement of its litigation with Celgene Corporation, and wholly owned subsidiary of Bristol Myers Squibb (NYSE: BMY) relating to patents for REVLIMID® (lenalidomide).

LogiNext Presents World’s First Complete COVID-19 Vaccine Supply Chain Management Platform

LogiNext today announced the launch of a COVID -19 vaccine supply chain management and tracking platform. Read more